PD-L1

Zapraszamy do zapoznania się z archiwalnymi szkoleniami online dotyczącymi diagnostyki genetycznej z użyciem kompleksu PD-L1.

Cykl wykładów Precision Pathology Insights przedstawia najbardziej istotne dla patologów tematy z zakresu diagnostyki PD-L1:

– Webinar 1: CPS masterclass – “Mastering Combined Positive Score (CPS): From Principles to Real-World Applications”

– Webinar 2: Changing times, reliable testing – “Implementation of PD-L1 Testing in the New Era of an Everchanging Immuno-Oncology Landscape”

– Webinar 3: Making the cut – “The Nuances of Tumor Types: How are Cutoffs Determined and Validated?”

– Webinar 4: Choice of platforms, consistent results – “PD-L1 IHC 22C3 pharmDx and NSCLC: One Assay, Two Platforms”

Tytuł	Data	Prelegent
The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA^® (pembrolizumab)	18 września 2019	Dr. Kristopher Kersch, MD, Pathologist, Agilent Technologies
The Value of Companion Diagnostic (CDx) IHC Assays in the Complex Environment of PD-L1 Testing	28 maja 2019	Dr. Allen Gown, BS (SUNY-Stony Brook), MD (Albert Einstein College of Medicine) Founder and Senior Pathologist, PhenoPath Laboratories; Clinical Professor, Dept. of Pathology, University of British Columbia
The Value of Participation in a PD-L1 EQA Program / PD-L1 Implementation in EQA Programs	26 października 2017	Professor Mogens Vyberg, University Hospital Aalborg, Denmark, and Andreas Scheel, MD, University Hospital Cologne, Germany
Introduction to PD-L1 Interpretation in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	17 pażdziernika 2017	Annika Eklund, PhD, and Debra Hanks, MD, Agilent Technologies, Inc.
Advanced PD-L1 Interpretation	27 wrzesnia 2017	Professor Hans-Ulrich Schildhaus, University Medical Center, Göttingen, Germany
Basic Interpretation of PD-L1 Expression	1 czerwca 2017	Professor Bharat Jasani, Targos Molecular Pathology GmbH, Kassel, Germany
How to Easily and Simply Implement PD-L1 Testing in Your Lab - Verification / Validation	20 kwietnia 2017	Carol Cheung, MD, PhD, JD, University Health Network, University of Toronto, Canada
A Blueprint for PD-L1 Testing - Development and Value of the PD-L1 22C3 Assay	6 kwietnia 2017	Kenneth J. Bloom, Head of Oncology and Immunotherapy, Human Longevity, Inc., San Diego, USA